Fremgangsmåde til fremstilling af en latanoprost-öjenoplösning og en således fremstillet oplösning
A method of solubilizing an analog active agent of the prostaglandin F2a, such as latanoprost, is described and a method of preparing an ophthalmic solution of the solubilized latanoprost for the treatment of distinct ocular ailments. This invention also refers to an ophthalmic aqueous solution resu...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Patent |
| Sprache: | dan |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | TORNERO MONTAÐO, JOSE RUBEN JIMENEZ BAYARDO, ARTURO LOPEZ SANCHEZ, MARYA ISABEL CRUZ OLMOS, ENRIQUE |
| description | A method of solubilizing an analog active agent of the prostaglandin F2a, such as latanoprost, is described and a method of preparing an ophthalmic solution of the solubilized latanoprost for the treatment of distinct ocular ailments. This invention also refers to an ophthalmic aqueous solution resulting from the aforementioned method, which is characterized by its chemical stability at room temperature, its safety, and innocuousness and efficiency in the treatment of the patient. The new ophthalmic aqueous solution is distinguished because its pharmaceutical value is found in the handling of a vehicle of easy access that not only permits the solubility of latanoprost, but also promotes its chemical stability and a greater tolerance of the patient with its ophthalmic application for the treatment of the patient's ailment. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_DK1759702TT3</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>DK1759702TT3</sourcerecordid><originalsourceid>FETCH-epo_espacenet_DK1759702TT33</originalsourceid><addsrcrecordid>eNrjZEh3K0rNTU_MSy_OPbw0JVWhJDNHIQ0oVAxk5GTmpSskpimk5inkJJYk5uUXFOUXl-ge3paVCmTnHN5WnAdSkZ8OUlF8eGlOakpqMUJ3aokCQhUPA2taYk5xKi-U5mZQdHMNcfbQTS3Ij08tLkhMTs1LLYl38TY0N7U0NzAKCTE2JkYNAAWaRMM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Fremgangsmåde til fremstilling af en latanoprost-öjenoplösning og en således fremstillet oplösning</title><source>esp@cenet</source><creator>TORNERO MONTAÐO, JOSE RUBEN ; JIMENEZ BAYARDO, ARTURO ; LOPEZ SANCHEZ, MARYA ISABEL ; CRUZ OLMOS, ENRIQUE</creator><creatorcontrib>TORNERO MONTAÐO, JOSE RUBEN ; JIMENEZ BAYARDO, ARTURO ; LOPEZ SANCHEZ, MARYA ISABEL ; CRUZ OLMOS, ENRIQUE</creatorcontrib><description>A method of solubilizing an analog active agent of the prostaglandin F2a, such as latanoprost, is described and a method of preparing an ophthalmic solution of the solubilized latanoprost for the treatment of distinct ocular ailments. This invention also refers to an ophthalmic aqueous solution resulting from the aforementioned method, which is characterized by its chemical stability at room temperature, its safety, and innocuousness and efficiency in the treatment of the patient. The new ophthalmic aqueous solution is distinguished because its pharmaceutical value is found in the handling of a vehicle of easy access that not only permits the solubility of latanoprost, but also promotes its chemical stability and a greater tolerance of the patient with its ophthalmic application for the treatment of the patient's ailment.</description><language>dan</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2009</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20090420&DB=EPODOC&CC=DK&NR=1759702T3$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25562,76317</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20090420&DB=EPODOC&CC=DK&NR=1759702T3$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>TORNERO MONTAÐO, JOSE RUBEN</creatorcontrib><creatorcontrib>JIMENEZ BAYARDO, ARTURO</creatorcontrib><creatorcontrib>LOPEZ SANCHEZ, MARYA ISABEL</creatorcontrib><creatorcontrib>CRUZ OLMOS, ENRIQUE</creatorcontrib><title>Fremgangsmåde til fremstilling af en latanoprost-öjenoplösning og en således fremstillet oplösning</title><description>A method of solubilizing an analog active agent of the prostaglandin F2a, such as latanoprost, is described and a method of preparing an ophthalmic solution of the solubilized latanoprost for the treatment of distinct ocular ailments. This invention also refers to an ophthalmic aqueous solution resulting from the aforementioned method, which is characterized by its chemical stability at room temperature, its safety, and innocuousness and efficiency in the treatment of the patient. The new ophthalmic aqueous solution is distinguished because its pharmaceutical value is found in the handling of a vehicle of easy access that not only permits the solubility of latanoprost, but also promotes its chemical stability and a greater tolerance of the patient with its ophthalmic application for the treatment of the patient's ailment.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2009</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZEh3K0rNTU_MSy_OPbw0JVWhJDNHIQ0oVAxk5GTmpSskpimk5inkJJYk5uUXFOUXl-ge3paVCmTnHN5WnAdSkZ8OUlF8eGlOakpqMUJ3aokCQhUPA2taYk5xKi-U5mZQdHMNcfbQTS3Ij08tLkhMTs1LLYl38TY0N7U0NzAKCTE2JkYNAAWaRMM</recordid><startdate>20090420</startdate><enddate>20090420</enddate><creator>TORNERO MONTAÐO, JOSE RUBEN</creator><creator>JIMENEZ BAYARDO, ARTURO</creator><creator>LOPEZ SANCHEZ, MARYA ISABEL</creator><creator>CRUZ OLMOS, ENRIQUE</creator><scope>EVB</scope></search><sort><creationdate>20090420</creationdate><title>Fremgangsmåde til fremstilling af en latanoprost-öjenoplösning og en således fremstillet oplösning</title><author>TORNERO MONTAÐO, JOSE RUBEN ; JIMENEZ BAYARDO, ARTURO ; LOPEZ SANCHEZ, MARYA ISABEL ; CRUZ OLMOS, ENRIQUE</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_DK1759702TT33</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>dan</language><creationdate>2009</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>TORNERO MONTAÐO, JOSE RUBEN</creatorcontrib><creatorcontrib>JIMENEZ BAYARDO, ARTURO</creatorcontrib><creatorcontrib>LOPEZ SANCHEZ, MARYA ISABEL</creatorcontrib><creatorcontrib>CRUZ OLMOS, ENRIQUE</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>TORNERO MONTAÐO, JOSE RUBEN</au><au>JIMENEZ BAYARDO, ARTURO</au><au>LOPEZ SANCHEZ, MARYA ISABEL</au><au>CRUZ OLMOS, ENRIQUE</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Fremgangsmåde til fremstilling af en latanoprost-öjenoplösning og en således fremstillet oplösning</title><date>2009-04-20</date><risdate>2009</risdate><abstract>A method of solubilizing an analog active agent of the prostaglandin F2a, such as latanoprost, is described and a method of preparing an ophthalmic solution of the solubilized latanoprost for the treatment of distinct ocular ailments. This invention also refers to an ophthalmic aqueous solution resulting from the aforementioned method, which is characterized by its chemical stability at room temperature, its safety, and innocuousness and efficiency in the treatment of the patient. The new ophthalmic aqueous solution is distinguished because its pharmaceutical value is found in the handling of a vehicle of easy access that not only permits the solubility of latanoprost, but also promotes its chemical stability and a greater tolerance of the patient with its ophthalmic application for the treatment of the patient's ailment.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | dan |
| recordid | cdi_epo_espacenet_DK1759702TT3 |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | Fremgangsmåde til fremstilling af en latanoprost-öjenoplösning og en således fremstillet oplösning |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T04%3A18%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=TORNERO%20MONTA%C3%90O,%20JOSE%20RUBEN&rft.date=2009-04-20&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EDK1759702TT3%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |